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Abstract
We have reviewed the pivotal presentations related to gastrointestinal malignancies from 2009 annual meeting of
the American Society of Clinical Oncology with the theme of “personalizing cancer care”. We have discussed the
scientific findings and the impact on practice guidelines and ongoing clinical trials. Adding trastuzumab to che-
motherapy improved the survival of patients with advanced gastric cancer overexpressing human epidermal
growth factor receptor 2. Gemcitabine plus cisplatin has become a new standard for first-line treatment of
advanced biliary cancer. Octreotide LAR significantly lengthened median time to tumor progression compared with
placebo in patients with metastatic neuroendocrine tumors of the midgut. Addition of oxaliplatin to fluoropyrimi-
dines for preoperative chemoradiotherapy in patients with stage II or III rectal cancer did not improve local tumor
response but increased toxicities. Bevacizumab did not provide additional benefit to chemotherapy in adjuvant
chemotherapy for stage II or III colon cancer. In patients with resected stage II colon cancer, recurrence score esti-
mated by multigene RT-PCR assay has been shown to provide additional risk stratification. In stage IV colorectal
cancer, data have supported the routine use of prophylactic skin treatment in patients receiving antibody against
epidermal growth factor receptor, and the use of upfront chemotherapy as initial management in patients with
synchronous metastasis without obstruction or bleeding from the primary site.
The prognosis of advanced gastrointestinal cancers has
improved modestly over the last two decades. In the
2009 annual meeting of the American Society of Clinical
Oncology (ASCO), it has become clear that targeted
therapies and personalized medicine for many cancer
types will soon become the standard of care. These data
contributed strongly towards the theme of the 2009
meeting - “Personalizing Cancer Care”.
First-line and targeted therapy for advanced
gastroesophageal cancer
Human epidermal growth factor receptor 2 (HER2)
exhibits tyrosine kinase activity and functions as a
growth factor receptor [1]. The overexpression of HER2
as a result of gene amplification has been demonstrated
in solid tumors such as breast and gastric cancers, and
correlates with aggressive course and poor prognosis
[2,3]. Immunohistochemistry (IHC) and fluorescent in-
situ hybridization (FISH) are commonly used to measure
HER2.
Pre-clinical studies have shown that trastuzumab, a
monoclonal antibody against HER2, causes cell cycle
arrest at G1 and exhibits antitumor activity in HER2
overexpressed gastric cancer [4,5]. Moreover, trastuzu-
mab can enhance chemotherapeutic efficacy in gastric
cancer xenograft with HER2 overexpression, when com-
bined with cytotoxic agents such as capecitabine, cispla-
tin, or taxane [6]. Phase II studies incorporating
trastuzumab with cisplatin-based regimen in patients
with advanced gastric cancer overexpressing HER2 have
shown encouraging activities [7,8].
The ToGA trial presented at ASCO 2009 screened
approximately 3,800 gastric cancer patients from
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24 countries [9]. They noted that HER2 expression was
detectable in 22% of patients and the concordance rate
between IHC and FISH was high at all levels of HER2
positivity [10]. There was a specific pattern of disease
which correlated with HER2 expression. Higher rates
occurred in intestinal and proximal or gastroesophageal
junction cancers than with diffuse or distal gastric can-
cers. Patients tested positive for HER2 expression were
enrolled into a large phase III trial comparing combina-
tion of fluoropyrimidine (5-fluorouracil [5-FU] or cape-
citabine) and cisplatin chemotherapy with or without
trastuzumab (Fig. 1). The primary study endpoint was
overall survival. The statistics were powered to detect a
survival improvement from 10 to 13 months with
hazard ratio of 0.77. In the final analysis, median overall
survival improved from 11 months with chemotherapy
alone, to 13.5 months with the addition of trastuzumab
(p = 0.0048). Response rate was 47% in the study arm
vs. 34% in the control arm. There were no differences in
the rates of congestive heart failure between the two
groups although there was a higher rate of asympto-
matic decrease in cardiac function in the trastuzumab
group. This is not altogether surprising as the median
duration of trastuzumab therapy (4.9 months) was
shorter than for breast cancer. This study demonstrated
that HER2 targeted therapy will be beneficial for 20-25%
of gastric cancer cases. The role of trastuzumab as a sin-
gle agent or as a part of perioperative therapy is worth
investigation.
Other targeted agents being investigated in the phase
II setting in gastroesophageal cancer include cetuximab
and bevacizumab. Both K-RAS and B-RAF gene muta-
tions are rare in gastric cancer and therefore cetuximab
may have an important therapeutic role. The
administration of bevacizumab was accompanied with a
small risk of bleeding or perforation. However, overall
these studies indicate that these combinations are feasi-
ble and result in impressive median overall survival
rates as compared with historical controls (Table 1;
[11-13]).
S-1 (TS-1®, Taiho Pharmaceutical Co., Ltd.) is an
orally active combination of tegafur (a 5-FU prodrug),
gimeracil (an inhibitor of dihydropyrimidine dehydro-
genase), and oteracil (which inhibits the phosphorylation
of 5-FU in the gastrointestinal tract, thereby reducing
the gastrointestinal toxic effects of 5-FU) and is widely
used in Asia for the management of gastric cancer.
Adjuvant therapy with S1 improved survival after gas-
trectomy and D2 dissection as compared with controls
in a prospective trial [14]. FLAGS trial, a phase III and
multi-center study, enrolled 1053 patients with advanced
gastric cancer, and compared cisplatin with either S-1 or
5-FU as first-line therapy [15]. The primary endpoint
was overall survival, and there was no overall survival
improvement with the S1-based regimen. However, toxi-
city was lower in S1 and cisplatin group as compared
with cisplatin and 5-FU in a subset analysis, and there
was an improvement in survival among patients with
the diffuse-type of gastric cancer. Updated findings of
JCOG 9912, which was a phase III study conducted in
Japan, were reported in 2009 ASCO meeting [16]. This
study compared 5-FU, irinotecan plus cisplatin, and S1
as first-line treatment in patients with advanced gastric
cancer, and the median survival figures were 10.8, 12.3
and 11.5 months, respectively. Although there was a sig-
nificant non-inferiority of S-1 to 5-FU (P < 0.001); how-
ever, either S-1 or irinotecan plus cisplatin failed to
show superiority to 5-FU (P = 0.034 and 0.055,
Figure 1 ToGA study design.
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respectively). Based on these results as well as the
FLAGS data, it is unlikely that S1 will be developed in
upper gastrointestinal cancers in the United States.
Treatment of localized gastroesophageal cancer
Neoadjuvant chemoradiotherapy (CRT) is commonly
used in the United States before esophagecomy for eso-
phageal cancer. The Southwest Oncology Group S0356
study demonstrated that oxaliplatin is safe in the neoad-
juvant setting and may potentially replace cisplatin
when given with concurrent 5-FU and radiation [17].
Schuhmacher et al. investigated the role of preoperative
5-FU, leucovorin (LV) and cisplatin chemotherapy for
operable gastric cancer [18]. Accrual was slow and the
study was stopped prematurely after enrolling 144
patients to surgery alone vs. preoperative therapy. There
was no significant survival improvement with preopera-
tive chemotherapy, although this resulted in lower mar-
gin-positive rate. In European countries, perioperative
chemotherapy based on the results of the MAGIC trial
with epirubicin, cisplatin and 5-FU is frequently used
and this approach will continue to be the standard of
care even after 2009 ASCO annual meeting [19].
The Eastern Cooperative Oncology Group (ECOG)
E2202 evaluated the safety of a novel form of esopha-
gectomy, called minimally invasive esophagectomy
(MIE) in a prospective multi-center trial. MIE involves
thoracoscopic and laparoscopic techniques in place of
‘open’ surgery [20]. As per the E2202 experience, MIE
can be performed safely with low post-operative mor-
bidity and mortality.
Hepatobiliary cancers
The mortality of cholangiocarcinoma is increasing
world-wide, particularly in areas with low incidence.
Part of this trend may be artifactual, as cancers formerly
described as ‘liver metastases of unknown primary’ are
increasingly being classified as intrahepatic cholangio-
carcinoma. Gemcitabine or fluoropyrimidines are com-
monly utilized for the treatment of advanced disease.
However, randomized, prospective trial data were lack-
ing in this disease. Valle et al. previously reported the
results of a phase II randomized trial of gemcitabine vs.
gemcitabine plus cisplatin for the treatment of advanced
biliary cancer [21]. In their phase II study, the median
time to tumor progression and 6-month progression-
free survival (the primary end point) were greater in the
gemcitabine and cisplatin arm vs. the gemcitabine-only
arm. Based on these results, they initiated a phase III,
multicenter trial of the two regimens for advanced bili-
ary cancer (ABC-02) patients, the results of which were
reported in ASCO 2009 meeting [22]. Four hundred and
ten patients were enrolled (including 149 patients with
gall bladder cancer) in a 1:1 randomized trial design.
The treatments were well-tolerated in both the arms,
surprisingly there was no added toxicity (hematological
or grade 3 or 4 non-hematological) despite the addition
of cisplatin. There was a significant improvement in sur-
vival noted in the gemcitabine plus cisplatin regimen as
compared with gemcitabine alone (11 vs. 8 months, p =
0.002). This was also accompanied by an improved pro-
gression-free survival. Gemcitabine plus cisplatin there-
fore becomes a new standard of care for patients with
advanced biliary cancer. It is expected that future strate-
gies will add targeted agents to this combination.
BINGO study is a randomized phase II study compar-
ing gemcitabine plus oxaliplatin chemotherapy alone or
in combination with cetuximab in patients with
advanced biliary cancer [23]. The interim safety analysis
of this randomized study indicated no added toxicity
with the addition of cetuximab; efficacy data are
awaited. Zhu et al. have combined gemcitabine and oxa-
liplatin with bevacizumab and demonstrated promising
efficacy of this combination in advanced biliary cancer
[24]. In this study, 18-fluorodeoxyglucose PET scan was
used to assess response, and PET responses correlated
with survival. Since this disease is often difficult to
assess the response by CT scan, further exploration of
PET imaging modality is warranted [25].
Transarterial hepatic chemoembolization (TACE) is
widely used for the management of regionally advanced
hepatocellular carcinoma (HCC). TACE improves local
control and is palliative, although its survival impact is
controversial. Recently, drug-eluting beads have been
employed for TACE in an attempt to increase the con-
trol rate. Lencioni et al. presented the results of a rando-
mized trial conducted in 212 patients with unresectable
HCC who were randomized to TACE with drug-eluting
beads uploaded with doxorubicin vs. conventional
TACE with doxorubicin-in-oil emulsion [26]. There was
a significant improvement in response rate 52% vs. 44%
with the drug-eluting beads, and this was also
Table 1 Phase II studies incorporating targeted agents in advanced gastroesophageal cancer
Targeted agent Chemotherapy N RR PFS (months) OS (months) Reference
Cetuximab Irinotecan and FU 49 42% 8.6 16.6 Kanzler et al. [11]
Bevacizumab Docetaxel, FU and cisplatin 44 67% 12 16.2 Kelsen et al. [12]
Cetuximab Irinotecan and oxaliplatin 51 60% 6 9.5 Woell et al. [13]
N: patient number; RR: response rate; PFS: progression-free survival; OS: overall survival; FU: 5-fluorouracil
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accompanied by a lower toxicity rate. This therapy is
also being investigated in other malignancies such as
neuroendocrine tumor and colorectal cancer (CRC)
[27,28].
Sorafenib has now become the standard first-line ther-
apy for advanced HCC after the results of the SHARP
trial [29]. There are no standard options after progres-
sion beyond first-line therapy with sorafenib. Kaseb et
al. presented the results of a phase II study of erlotinib
and bevacizumab for advanced HCC [30]. Toxicity asso-
ciated with this regimen was acceptable and the
response rate was impressive at 28%. The overall survi-
val was 12 months, and responses were noted in
patients who had received prior systemic therapy. Based
on these encouraging results, a randomized phase II
study of bevacizumab plus erlotinib vs. sorafenib as
first-line therapy in patients with advanced HCC is
being conducted.
Brivanib is a dual tyrosine kinase inhibitor of vascular
endothelial growth factor receptor and fibroblast growth
factor receptor. Raoul et al. reported the results of a
phase II study of brivanib in 96 patients (38 of them
failed prior sorafenib) with advanced HCC [31]. The
median survival of patients without prior systemic ther-
apy was 10 months. Anti-tumor effect was noted in
patient received no prior systemic therapy and in
patients failed prior sorafenib treatment. Fatigue, hypo-
natremia, diarrhea and hypertension were the important
toxicities noted. Randomized phase III studies of first-
line treatment comparing brivanib vs. sorafenib, and
second-line treatment comparing best supportive care
plus brivanib vs. best supportive care with placebo in
patients with advanced HCC are ongoing.
Pancreatic cancer
The study conducted by Gastrointestinal Tumor Study
Group in the late 1970s and early 1980s showed that
adjuvant therapy with 5-FU plus radiotherapy followed
by maintenance 5-FU chemotherapy after surgical resec-
tion for pancreatic cancer improved the overall survival
[32]. The subsequent ESPAC-1 study suggested that 5-
FU chemotherapy was superior to CRT in the adjuvant
setting [33]. CONKO-001 study proved that adjuvant
gemcitabine was superior to observation [34]. In 2009
ASCO meeting, the results of ESPAC-3, the largest adju-
vant study for pancreatic cancer, were presented [35].
This study compared 5-FU plus LV vs. gemcitabine in
1088 patients after curative pancreatectomy, enrolled in
16 countries, mostly in Europe. There was no statisti-
cally significant survival difference between these two
arms. Thus even in 2009, there appears to be no regi-
men better than 5-FU as adjuvant therapy in resected
pancreatic cancer. The ESPAC group has launched a
subsequent phase III study comparing gemcitabine plus
capecitabine vs. gemcitabine. In tertiary institutions
across the U.S., neoadjuvant therapy is gathering
momentum as it appears to limit surgery to those most
likely to benefit by excluding the cancers that have
aggressive biology. American College of Surgeons
Oncology Group has launched a phase II study of
neoadjuvant chemotherapy with gemcitabine and erloti-
nib followed by pancreatectomy and postoperative adju-
vant chemotherapy with gemcitabine and erlotinib for
patients with operable pancreatic cancer.
Deep vein thrombosis (DVT) is a commonly encoun-
tered problem in patients with pancreatic cancer. Pro-
thrombotic factors generated by the cancer cells, debility
of the patients, dehydration and systemic chemotherapy
have been thought to be the attributing factors. DVT in
pancreatic cancer patients is associated with a poor
prognosis and therefore its prevention is required. The
CONKO-004 study randomized 300 patients with pan-
creatic cancer receiving gemcitabine-based chemother-
apy to low-molecular weight heparin (enoxaparin) or
observation [36]. The primary endpoint was DVT occur-
rence in the first 3 months, during which patients
received higher dose of enoxaparin (1 mg/kg/day). The
secondary endpoint was overall survival. The investiga-
tors noted that the incidence of DVT was lower in the
treatment arm as compared with the observation arm
(10% vs. 1.3%), without any increase in the bleeding risk.
However, there was no survival difference between these
two arms.
Newer agents that appear to be promising in pancrea-
tic cancer include abraxane, albumin-bound paclitaxel.
Von Hoff et al. presented the preliminary efficacy data
of the gemcitabine plus abraxane combination for
patients with advanced pancreatic cancer [37]. In this
study, PET scan was used to measure response. They
observed 23% complete metabolic response and more
than 60% disease control rate (complete response, par-
tial response and stable disease). The median overall
survival was 9 months and there was a correlation
between the expression of secreted protein acid rich in
cysteine (SPARC) and clinical outcome. This regimen is
currently being investigated in a randomized phase III
study.
Promising results were also reported with cationic
liposomal paclitaxel (EndoTAG-1) in combination with
gemcitabine; a median survival of 11.5 months was
noted in this study without serious toxicity [38]. These
two studies underscore the efficacy of taxanes in this
disease and the importance of drug delivery using the
nanoparticle formulations. Insulin-like growth factor 1
receptor (IGF1R) targeted antibodies and tyrosine kinase
inhibitors are being investigated in a variety of tumor
types including pancreatic cancer. Investigators from
MD Anderson Cancer Center presented data on genetic
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variations in the IGF1R pathway and prognosis in locally
advanced pancreatic cancer [39]. In their analysis of 105
patients, a clear genotypic profile emerged which corre-
lated with an adverse outcome and could potentially be
targeted by IGF1R inhibitors.
Neuroendocrine tumors
Long-acting somatostatin analogues are widely used for
symptomatic, low-grade neuroendocrine tumors such as
carcinoids. The survival impact of this therapy was
never examined prospectively. The PROMID study ran-
domly assigned patients with inoperable metastatic neu-
roendocrine tumors with well-differentiated tumor
histology to either placebo or octreotide LAR 30 mg
intramuscularly every month until tumor progression
[40,41]. The primary end point was time to progression,
and secondary end points were survival and response
rate. The study was conducted in Germany and planned
the enrollment of 162 patients. However, enrollment
stopped after an interim analysis of 85 patients as the
median time to tumor progression in the octreotide
LAR group was 15.6 months versus 5.9 months in the
placebo group (p = 0.00072) after 6 months of treat-
ment. The most favorable effect was observed in
patients with low hepatic tumor load (< 10%) and
resected primary tumors. The authors concluded that
octreotide LAR significantly lengthens median time to
tumor progression compared with placebo in patients
with functionally active and inactive metastatic neuroen-
docrine tumors of the midgut. This study is likely to
expand the use of somatostatin analogues to this sub-
group of patients although it should be noted that these
results are based on a limited cohort of patients for
whom no overall survival data is currently available.
Anal cancer
Squamous cell carcinoma of anus is an uncommon
malignancy of lower gastrointestinal tract. Several ran-
domized studies have established CRT with 5-FU and
mitomycin-C (MMC) as standard treatment yielding
high rates of local control and 5-year disease-free survi-
val without needing surgery or colostomy [42-44]. Due
to frequent occurrence of severe toxicities associated
with MMC, several phase II studies have used cisplatin
instead of MMC in combination with 5-FU and radio-
therapy with promising results [45,46]. RTOG 98-11, a
US Gastrointestinal Intergroup trial, compared CRT
with 5-FU plus MMC vs. neoadjuvant chemotherapy
with 5-FU plus cisplatin followed by CRT with 5-FU
and cisplatin. In this study, cisplatin-based regimen was
shown to be less effective than MMC-based regimen
[44]. The main criticism for this study is induction che-
motherapy may provide detrimental effect due to delay
in starting radiotherapy [47].
James et al. presented a randomized trial of anal can-
cer from the United Kingdom (ACT II) using 2 × 2
design comparing 5-FU with either cisplatin or MMC
during CRT, followed by either observation or two
cycles of maintenance chemotherapy with cisplatin and
5-FU [48]. Response to CRT was excellent with about
95% of patients achieving a complete response at 6
months with either MMC or cisplatin-based regimen.
Moreover, maintenance chemotherapy didn’t affect dis-
ease-free or overall survival at three years, with 75% of
patients without recurrences whether receiving mainte-
nance chemotherapy or not. Although the rates of non-
hematological toxicities were similar between MMC and
cisplatin-based regimens, patients receiving MMC-based
regimen had more grade 3/4 hematological toxicities (25
vs. 13%, p < 0.001). CRT with MMC and 5-FU remains
the standard treatment for anal cancer, and there is no
benefit for giving chemotherapy before or after CRT. In
circumstances such as shortage of MMC or necessity to
avoid severe hematological toxicities, cisplatin may
replace MMC for the treatment of anal cancer.
Rectal cancer
Rectal cancer carries a high chance of local recurrence.
Preoperative radiation therapy was compared with preo-
perative CRT with 5-FU in patients with locally
advanced rectal cancer (LARC) including stage II or III
rectal cancer, in French FFCD 9203 and European Orga-
nization for Research and Treatment of Cancer
(EORTC) 22921 studies. Improved local control rate
was noted in patients receiving CRT [49,50]. In French
FFCD 9203 study, combined treatment led to improved
pathologic complete response of 11.4% (vs. 3.6% in the
radiation arm) and improved 5-year local failure rates
(8.1% vs. 16.5%, respectively). Therefore, neoadjuvant
CRT is considered a standard treatment for patients
with LARC such as T3 or T4 lesion or with regional
lymph node involvement.
Data from phase I to II trials have shown that adding
weekly oxaliplatin to 5-FU or capecitabine in preopera-
tive CRT may improve pathologic response with accep-
table grade 3/4 toxicities in patients with LARC [51,52].
Three randomized phase III studies, STAR-01 (primary
objective: overall survival), ACCORD 12/0405 PRODIGE
2 (primary objective: pathological complete response)
and National Surgical Adjuvant Breast and Bowel Pro-
ject (NSABP) R-04, have been conducted to study the
role of oxaliplatin in the neoadjuvant CRT for LARC.
NSABP R-04 by far has the largest target patient num-
ber (~1600) with primary objective to compare the rates
of local-regional tumor relapse, and has reached more
than 80% of the accrual target since July 2004 [53]. The
trial was initially designed as a 2-arm study to compare
5-FU vs. capecitabine, and amended in January 2006 to
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a 2 × 2 design comparing 5-FU vs. capecitabine with/
without weekly oxaliplatin as preoperative CRT in
patients with LARC.
STAR-01 and ACCORD 12/0405 PRODIGE 2 were
presented in 2009 ASCO meeting. The investigational
arms in both studies received weekly oxaliplatin to CRT
with either 5-FU or capecitabine. As shown in Table 2,
both studies showed addition of oxaliplatin to chemora-
diotherapy significantly increased grade 3/4 toxicities
without affecting local tumor response [54,55]. There
were no improvement in the rate of complete responses
found at surgery, and no decrease in the number of
patients requiring permanent colostomy, when compar-
ing oxaliplatin arm to standard treatment arm. The
exploratory analyses have identified reduced incidence
of metastatic disease by oxaliplatin in both studies.
Longer follow-up is needed to assess the impact on sur-
vival endpoints.
Adjuvant chemotherapy for colon cancer
Monoclonal antibodies directed against vascular
endothelial growth factor and epidermal growth factor
receptor have been approved to be used in stage IV
CRC, but the benefit of these biologic agents in patients
with stage II/III disease remains unknown. NSABP C-08
is a phase III randomized study enrolling ~2,700
patients with stage II/III colon cancer after surgery to
compare a modified FOLFOX regimen known as mFO-
LOX6 (every 2 weeks for 12 cycles) vs. bevacizumab and
mFOLFOX6 (every 2 weeks for 12 cycles then bevacizu-
mab alone every 2 weeks for 14 cycles) as adjuvant ther-
apy. The safety report was first presented in 2008 ASCO
annual meeting, which demonstrated well-balanced
grade 4/5 toxicities in each arm [56].
In 2009 ASCO annual meeting, Wolmark et al. pre-
sented the efficacy result from this study [57]. Although
improvement in disease-free survival (DFS) was
observed during the first year in bevacizumab arm
(94.3% vs. 90.7%; p = 0.004), the magnitude of this
benefit became gradually attenuated with time when
patients were no longer on bevacizumab. There was no
significant difference in DFS at 3 years (77.4% vs. 75.5%
for FOLOFOX group; p = 0.15). Subgroup analysis
showed bevacizumab did not improve 3-year DFS for
either stage II (~25% of study patients) or stage III.
The companion study of NSABP C-08 is AVANT
(BO17920), which is a three-arm, international phase III
study in patients with resected stage III or high-risk
stage II colon cancer [58]. High-risk stage II disease is
defined by any one of the followings: T4 tumor, bowel
obstruction or perforation, histological signs of vascular
invasion or perineural invasion, age < 50 years, or < 12
lymph nodes analyzed. This study has enrolled ~3450
patients to receive FOLFOX-4 plus bevacizumab or
XELOX (capecitabine and oxaliplatin) plus bevacizumab
or FOLFOX-4 alone for 24 weeks. Patients in the beva-
cizumab arms continued to receive bevacizumab for
additional 24 weeks, whereas patients in the FOLFOX
arm were observed. The primary endpoint of this study
is to compare 3-year DFS, and the result is expected to
be available in 2010.
North Central Cancer Treatment Group (NCCTG)
N0147 and Pan-European Trials in Adjuvant Colon
Cancer (PETACC)-8 are two phase III adjuvant studies
enrolling patients with resected stage III colon cancer to
receive either FOLFOX or FOLFOX plus Cetuximab for
6 months [59]. Since initiation in 2005, there have been
more than 4,000 patients all together enrolled in these 2
studies with primary endpoint of comparing 3-year DFS.
Both studies have been amended in 2008 after ASCO
annual meeting to randomize patients only with wild-
type K-RAS tumors. The interim analysis of PETACC-8
is expected in 2011. The pre-planned interim analysis of
N0147 has concluded cetuximab plus FOLFOX did not
improve 3-year DFS even in patients with wild-type K-
RAS tumors. Therefore, N0147 was permanently closed
on November 25, 2009, and the cetuximab treatment
was discontinued simultaneously.
Table 2 Two phase III studies investigating the role of adding oxaliplatin to preoperative chemoradiotherapy in rectal
cancer
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capecitabine
299 11% 73% 14% 4%





N: patient number; LAR: low anterior resection; pCR: pathological complete response
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Prognostic and predictive biomarkers for stage II colon
cancer
Approximately 75-80% of patients with stage II colon
cancer are cured with surgery alone, and the benefit of
adjuvant chemotherapy is controversial [60]. The Inter-
national Multicentre Pooled Analysis of B2 Colon Can-
cer Trials (IMPACT B2) has pooled the stage II
populations of five similar randomized trials comparing
5-FU and LV vs. observation. This study included 1,016
patients, and failed to demonstrate any effect of che-
motherapy [61]. The United Kingdom QUASAR study
which included more than 2,000 patients with stage II
colon cancer has shown chemotherapy with 5-FU and
LV provided a small improvement (~4%) in rates of
recurrence and overall survival (OS) compared to
patients on observation [62]. Oncologists have fre-
quently used clinical and pathological features such as
tumor stage (T3 vs. T4), tumor perforation, inadequately
sampled lymph nodes (<12), poor tumor cell differentia-
tion, and extramural venous invasion, to identify
patients who may harbor higher risk for recurrence and
potentially benefit from adjuvant chemotherapy [63].
Most of these features are not informative for the
majority of patients, and have never been validated in
perspective studies.
Emerging data have shown that microsatellite instabil-
ity (MSI) and chromosome 18q loss of heterozygosity
(18qLOH) in colon cancer may be useful as molecular
prognostic markers in patients with stage II/III colon
cancer [56,64,65]. The ongoing ECOG 5202 study is a
perspective study in stage II colon cancer to identify
high-risk patients for adjuvant treatment using molecu-
lar marker analysis including MSI and 18qLOH [66].
Bertagnolli et al presented 18qLOH analysis from
Cancer and Leukemia Group B (CALGB) protocol 9581,
which randomized 1738 patients with stage II colon
cancer to postoperative treatment with monoclonal anti-
body 17-1A or observation [67]. The result was initially
reported in 2004 ASCO annual meeting. There was no
difference in 5-year DFS and OS between patients
receiving treatment and on observation. Among these
patients, 537 tumor samples were obtained for molecu-
lar marker analysis, and 23% had MSI. Of the remaining
samples, 101 tumor samples had 18qLOH, and 49 had
intact 18q. There were significant differences in OS (98
vs. 85 m) and DFS (92 vs. 78 m) between patients with
intact 18q and 18qLOH favoring patients with intact
18q. This result is in consistent with prior report that
LOH at 18q is prognostic for DFS and OS in patients
with early-stage colon cancer did not receive che-
motherapy after surgery [65].
In an effort to develop new clinical tools for risk
assessment and treatment decisions in stage II colon
cancer, Kerr et al. presented the multi-gene expression
assay in patients with stage II colon cancer [68]. This
assay is to use real-time RT-PCR to quantitate RNA
derived from paraffin-embedded tumor tissue [69]. They
have initially identified 761 candidate genes from 1,851
patients’ tumor samples in NSABP C-01/C-02/C-04/
C-06 and Cleveland Clinic study. After further modeling
and analysis, they have prospectively defined the recur-
rence score based on 7 genes associated with recurrence
risk (stromal related genes: FAP, INHBA, BGN; cell-
cycle related genes: Ki-67, C-MYC, MYBL-2; and
GADD45B). Additionally, 6 genes were chosen and
defined as treatment score. The recurrence and treat-
ment scores were validated in 1,436 tumor samples (711
with surgery alone, and 725 with surgery plus adjuvant
chemotherapy with 5-FU and LV) from QUASAR study.
In 725 patients receiving surgery and adjuvant che-
motherapy with 5-FU and LV, treatment score did not
predict benefit of adjuvant chemotherapy.
In 711 patients receiving surgery alone, there was sig-
nificant association between recurrence score and risk
of recurrence at 3 years following surgery (P = .004).
There were 43.7% in low-risk group (<30 recurrence
score), 30.7% in intermediate group and 25.6% in high-
risk group (> = 41 recurrence score). Estimated 3-year
recurrence risk is 12% (95% CI 9-16%), 18% (95% CI
13-24), and 22% (95% CI 16-29), respectively in low-
risk, intermediate and high-risk groups. Multivariate
analyses identified three key independent predictors of
recurrence in stage II colon cancer after surgery: T4
stage, MSI and recurrence score. In patients with T3
tumor and negative for MSI (~76% of stage II), recur-
rence score was found to be useful in predicting indivi-
dual risk of recurrence. This is the first demonstration
of a prospectively defined gene expression assay inde-
pendently predicting risk of recurrence in stage II colon
cancer after surgery.
The translational studies of PETACC 3/EORTC
40993/SAKK 60-00 trial were presented in this year’s
ASCO meeting [70,71]. This study randomized 3,278
patients with stage II or III colon cancer after surgery to
5-FU/LV or 5-FU/LV/irinotecan [72]. There was no sig-
nificant difference in 5-yr DFS between these 2 treat-
ment arms. Tumor samples were available from 1,404
patients, and MSI was analyzed in 1,327 samples. There
was higher incidence of MSI in stage II (22%) vs. stage
III (12%). MSI was a significant prognostic factor for
relapse-free survival (HR 0.265, p = 0.0044) and overall
survival (median follow up 68 months, HR 0.159, p =
0.011) in stage II colon cancer. There was no significant
association between prognosis and MSI in stage III
colon cancer, and this may be due to small sample size
or possible stage specific biological effects. However,
MSI was not predictive for the efficacy of irinotecan/5-
FU/LV treatment in this study, which differed from the
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analysis in CALGB 89803 [73]. Both p53 and the
SMAD4 genes had prognostic value for stage III but not
for stage II colon cancer. Contradictory to previously
published report, 18qLOH failed to demonstrate prog-
nostic value in stage II or III colon cancer. These find-
ings suggest that stage II and III colon cancers may
differ biologically.
Metastatic colorectal cancer: Management of skin rash in
patients receiving antibody against epidermal growth
factor receptor
Skin rash is the most common side effect for patients
receiving antibody against epidermal growth factor
receptor such as panitumumab. Severe skin rash may
delay or interrupt treatment, therefore reducing the
effectiveness of treatment. Mitchell et al. presented a
randomized study comparing prophylactic skin treat-
ment vs. reactive skin toxicity treatment (treatment after
skin rash developed) in 95 patients with metastatic CRC
receiving panitumumab-based chemotherapy [74]. Forty-
eight patients received prophylactic skin treatment
including topically applied sunscreen, moisturizers and
corticosteroids with oral antibiotics (doxycycline) start-
ing 24 hours before the first dose of panitumumab, and
47 patients to reactive skin toxicity treatment. Twenty-
nine percent of patients in the prophylactic group
experienced skin toxicity vs. 62% of those in the reactive
treatment group. The incidence of grade 2 or higher
skin toxicities was significantly decreased by prophylac-
tic skin treatment. Only 1% of patients in the prophylac-
tic skin treatment arm experienced a dose delay
compared with 6% of patients in the reactive skin treat-
ment arm. The data is supportive of the routine use of
prophylactic skin treatment in patients receiving epider-
mal growth factor receptor inhibitors.
Metastatic colorectal cancer: Upfront chemotherapy in
patients with synchronous metastasis
In patients with newly-diagnosed CRC with synchronous
metastasis, the benefit of immediate resection of primary
tumor in the absence of symptoms (i.e. bleeding, per-
foration or obstruction) is unclear. Retrospective ana-
lyses in the pre-target therapy era have shown that
resection of asymptomatic primary tumors was fre-
quently associated with prolonged survival, but was not
found to significantly reduce the incidence of life-threa-
tening tumor-related complications [75-77].
Poultsides et al. presented a retrospective reviewed of
233 patients with synchronous metastatic CRC and
unresected primary tumors treated with upfront che-
motherapy in a single institute [78]. Patients received
FOLFOX or irinotecan plus 5-FU and LV with or with-
out bevacizumab as initial treatment. Two hundred
seventeen patients (93%) never required surgery to
palliate primary tumor related complications. Ten
patients (4%) required nonsurgical intervention such as
stent or radiotherapy for symptomatic management of
the primary site. Neither use of bevacizumab, location
of the primary tumor in the rectum, or metastatic dis-
ease burden was associated with increased intervention
rate. Their findings support the use of upfront che-
motherapy as initial management for patients with syn-
chronous stage IV CRC without obstruction or bleeding
from the primary site.
The ongoing perspective phase II study, NSABP C-10,
will provide more data in the upfront nonsurgical
approach [79]. C-10 has been activated since March
2006, and plans to enroll 90 patients with unresectable
stage IV colon cancer and synchronous asymptomatic
primary tumor. Patients are treated with bevacizumab
and FOLFOX without prophylactic resection of the pri-
mary tumor. The primary objective is the rate of pri-
mary tumor-related events (i.e. obstruction, perforation,
fistula, and hemorrhage) that necessitate surgery.
Summary
We have discussed important presentations in gastro-
intestinal oncology from 2009 annual meeting of
ASCO. The key findings are summarized as the follow-
ings, and will lead to paradigm change in clinical prac-
tice. Adding trastuzumab to chemotherapy improved
the survival of patients with advanced gastric cancer
overexpressing HER2. Gemcitabine plus cisplatin has
become a new standard for first-line treatment of
advanced biliary cancer. Octreotide LAR significantly
lengthened median time to tumor progression com-
pared with placebo in patients with metastatic neu-
roendocrine tumors of the midgut. In patients with
resected stage II colon cancer, recurrence score esti-
mated by multigene RT-PCR assay has been shown to
provide additional risk stratification. In stage IV CRC,
data have supported the routine use of prophylactic
skin treatment including oral antibiotics in patients
receiving epidermal growth factor receptor antibody,
and the use of upfront chemotherapy as initial man-
agement in patients with synchronous metastasis with-
out obstruction or bleeding from the primary site.
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